583 related articles for article (PubMed ID: 17187456)
1. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
2. ADP receptors: inhibitory strategies for antiplatelet therapy.
Cattaneo M
Drug News Perspect; 2006 Jun; 19(5):253-9. PubMed ID: 16941047
[TBL] [Abstract][Full Text] [Related]
3. ADP receptors: inhibitory strategies for antiplatelet therapy.
Cattaneo M
Timely Top Med Cardiovasc Dis; 2006 Sep; 10():E22. PubMed ID: 17066149
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
5. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
7. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
Gachet C
Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
[TBL] [Abstract][Full Text] [Related]
8. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Raju NC; Eikelboom JW; Hirsh J
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
[TBL] [Abstract][Full Text] [Related]
9. P2Y receptor antagonists in thrombosis.
Boeynaems JM; van Giezen H; Savi P; Herbert JM
Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
11. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
12. Platelet P2Y12 receptor inhibition by thienopyridines: status and future.
Porto I; Giubilato S; De Maria GL; Biasucci LM; Crea F
Expert Opin Investig Drugs; 2009 Sep; 18(9):1317-32. PubMed ID: 19678800
[TBL] [Abstract][Full Text] [Related]
13. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
14. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
15. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
16. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
17. Novel antiplatelet strategies in acute coronary syndromes.
Sabatine MS
Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
19. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Cattaneo M
Thromb Haemost; 2011 May; 105 Suppl 1():S67-74. PubMed ID: 21479342
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Capranzano P; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
